Pier Luigi Zinzani
SESSION I: A 5-Year look at three amazing therapeutic “SUDOKU puzzle”

P.L. Zinzani

Diffuse large B-cell lymphoma
G. Salles
Multiple myeloma
S. Kumar
SESSION II: CAR-T

S.J. Schuster

Second generation auto-CAR-T
S.J. Schuster
Allogeneic CAR-T: do they have a real future?
S.S. Neelapu
In vivo CAR-T
T. Siddiqi
SESSION III: News in Hodgkin’s lymphoma

R.H. Advani

Actual scenario in frontline advanced stage
P. Borchmann
The therapeutic algorithm for elderly and “old old” patients
G. Collins
CAR-T: can we see the light at the end of the tunnel?
F. Locatelli
LECTURES: update on BTK/BCL6 degraders

P.L. Zinzani

ZelebrudoMIDE (NX-2127) and bexobrutiDEG (NX-5948)
A.V. Danilov
Bifunctional cereblon-dependent ligand-directed degrader of B cell lymphoma 6
G. Salles
SESSION IV: Acute leukemias

A. Venditti

BCL-2 inhibitors in AML: venetoclax and beyond
T. Cluzeau
Antibody-drug conjugates in AML: novel targets for novel drugs
C. Sartor
IDH inhibitors in AML
S. De Botton
Targeting FLT3: how to choose among inhibitors
A.E. Perl
Menin-inhibitors in AML and ALL
C. Papayannidis
Immunotherapies in AML and ALL
M. Subklewe
SESSION V: Classical Ph1-neg myeloproliferative neoplasms

P. Guglielmelli, F. Palandri

Interferons and epigenetic modulators: redefining the therapeutic landscape in PV
F. Palandri
Iron metabolism modifiers in PV
M. Kremyanskaya
Evolving strategies for cytopenic myelofibrosis
P. Guglielmelli
Epigenetic modifiers and pro-apoptotic agents in myelofibrosis
P. Vachhani
Monoclonal and bispecific antibodies targeting mutant CALR
A. Rampotas
Best timing and patient selection for allogeneic transplantation in MF
N. Kröger
SESSION VI: Non-Hodgkin’s lymphoma (I)

C. Carlo-Stella

Bispecific antibodies in combinations - Epcoriab
L. Falchi
Bispecific antibodies in combinations -Glofitamab
G. Iacoboni
Bispecific antibodies in combinations - Mosunetuzumab
E. Budde
Bispecific antibodies in combinations -Odronextamab
W.S. Kim
New bispecific and trispecific antibodies- Surovatamig
S. Gaballa
New bispecific and trispecific antibodies - BAFFR bispecific
K. Patel
New bispecific and trispecific antibodies -Trispecific antibodies
M. Subklewe
Monoclonal antibodies and ADC combinations - Tafasitamab combinations
J. Düll
Monoclonal antibodies and ADC combinations - Loncastuximab combinations
J.P. Alderuccio
Monoclonal antibodies and ADC combinations - Polatuzumab combinations
M. Matasar
SESSION VII: Non-Hodgkin’s lymphoma (II)

M. Martelli

BTK inhibitors combinations - Ibrutinib
K. Patel
BTK inhibitors combinations - Acalabrutinib
P. Strati
BTK inhibitors combinations - Pirtobrutinib
M. Wang
BCL-2 inhibitors - Sonrotoclax
M. Wang
SESSION VIII: Non-Hodgkin’s lymphoma (III)

A. Pinto, M. Spina

DZD8586, a non-covalent BBB penetrant LYN/BTK inhibitor
Y. Song
Golcadomide
J.M. Michot
Mogamulizumab in combinations
A. De Masson
Zeprumetostat (SHR2554)
Y. Song
Dibotatug (DR-01)
S.P. Iyer
SESSION IX: Chronic myeloid leukemia

F. Castagnetti

CML treatment recommendations
H. Hjorth-Hansen
Ponatinib
F. Castagnetti
Olverembatinib
D. Rea
TERN-701, ELVN-001 and other new agents
M. Mauro
LECTURES

A. Tedeschi

Novel therapies for Waldenström’s macroglobulinemia
S. Treon
SESSION X: Chronic lymphocitic leukemia

P. Sportoletti, A. Tedeschi

First line: - Until the progression
S. Stilgenbauer
Fixed duration
M.S. Davids
Round table: analyzing the guide lines!

Chairman: P. Ghia Discussants: P.M. Barr, M.S. Davids, W. Jurczak, S. Stilgenbauer

Pirtobrutinib
P.M. Barr
Novel agents
W. Jurczak
SESSION XI: Multiple myeloma

J. Kaufman, E. Zamagni

New CARTs in relapsed/refractory patients
T. Martin
Bispecifics in combination and trispecifics in relapsed/refractory patients
N. van de Donk
Celmods alone and in combination in newly diagnosed and relapsed/refractory patients
J. Kaufman
Privacy Policy | Cookie Policy